Jinwu Financial News | According to the Hong Kong Stock Exchange disclosure on January 29, Leisure Defender submitted a listing application to the main board of the Hong Kong Stock Exchange, with CITIC Securities and CCB International as co-sponsors. It is worth noting that the stock has already been listed on the Beijing Stock Exchange. If the process goes well, it is expected to become the first company listed in the “North+H” region.

The company is a clinical-stage vaccine developer in China. It has the richest HPV vaccine product portfolio in the world, and is transitioning from biotechnology research and development to commercialization. The company's three HPV vaccine combinations have high commercial popularity, leading the industry to meet the needs of different groups of people for different services.

On the financial side, the company recorded revenue of 1.901 million yuan and 1.601 million yuan respectively in 2022 and the first 9 months of 2023, corresponding losses of 293 million yuan and 225 million yuan due to parent company owners during the same period.